IP Library › Granted Patent US 12,589,137
Granted Patent B2
US 12,589,137 · App. 17/587,253 · Granted Mar 31, 2026

Compositions and methods for treating pathological calcification and ossification

Inventors: Demetrios Braddock (Guilford, CT); Ronald Albright (Guilford, CT)
Assignee: YALE UNIVERSITY
A61K38/465A61K38/46C12N9/14C12N9/16C12Y301/04001C12Y306/01009C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,589,137
App. No.
17/587,253
Granted
Mar 31, 2026
Kind
B2
Abstract

The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.

Claims (19)

1 . A method of treating or ameliorating a disease or disorder associated with or caused by an improper serum pyrophosphate (PPi) and phosphate (Pi) balance (PPi/Pi homeostasis) in a subject,

the method comprising administering to the subject a therapeutically effective amount of a composition comprising a soluble ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) polypeptide or a biologically active fragment, derivative, mutant, or mutant fragment thereof,

wherein the soluble ENPP1 polypeptide lacks a targeting domain consisting of 4-20 sequential aspartic acid residues,

wherein the administering increases serum PPi levels in the subject relative to the serum PPi levels in the subject before the administration, and thereby treating or ameliorating the disease or disorder in the subject.

2 . The method of claim 1 , wherein the soluble ENPP1 polypeptide comprises a somatomedin B domain, an ENPP1 catalytic domain, and an ENPP1 nuclease domain.

3 . The method of claim 1 , wherein the soluble ENPP1 polypeptide comprises residues 96-925 of human ENPP1 (SEQ ID NO: 1).

4 . The method of claim 1 , wherein the soluble ENPP1 polypeptide is a secreted product of a precursor polypeptide expressed in a mammalian cell, wherein the precursor polypeptide comprises an ecto-nucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) signal sequence and an ENPP1 polypeptide, wherein the precursor polypeptide undergoes proteolytic processing to the soluble ENPP1 polypeptide.

5 . The method of claim 1 , wherein the soluble ENPP1 polypeptide is a secreted product of a precursor polypeptide expressed in a mammalian cell, wherein the precursor polypeptide comprises residues 12-30 of ENPP2 (SEQ ID NO: 2), which is fused to the N-terminus of a polypeptide comprising a somatomedin B domain, an ENPP1 catalytic domain, and an ENPP1 nuclease domain, wherein the precursor polypeptide undergoes proteolytic processing to the soluble ENPP1 polypeptide.

6 . The method of claim 1 , wherein the soluble ENPP1 polypeptide is a secreted product of a precursor polypeptide expressed in a mammalian cell, wherein the precursor polypeptide lacks residues 77-98 of the ENPP1 transmembrane domain and comprises a signal sequence, wherein the precursor polypeptide undergoes proteolytic processing to the soluble ENPP1 polypeptide.

7 . The method of claim 1 , wherein the ENPP1 polypeptide is a secreted product of a precursor polypeptide expressed in a mammalian cell, wherein the precursor polypeptide comprises residues 1-76 of ENPP1 (SEQ ID NO: 1), residues 12-30 of ENPP2 (SEQ ID NO: 2), and residues 96-925 of ENPP1 (SEQ ID NO: 1), wherein the precursor polypeptide undergoes proteolytic processing to the soluble ENPP1 polypeptide.

8 . The method of claim 1 , wherein the soluble ENPP1 polypeptide is a fusion protein comprising an IgG Fc domain.

9 . The method of claim 1 , wherein the soluble ENPP1 polypeptide has ATP hydrolytic activity.

10 . The method of claim 1 , wherein the soluble ENPP1 polypeptide is administered acutely or chronically to the subject.

11 . The method of claim 6 , wherein the soluble ENPP1 polypeptide is administered locally, regionally, parenterally, or systemically to the subject.

12 . The method of claim 1 , wherein the subject is human.

13 . The method of claim 1 , wherein the disease or disorder is at least one selected from the group consisting of idiopathic infantile arterial calcification (IIAC), ossification of the posterior longitudinal ligament (OPLL), hypophosphatemic rickets, osteoarthritis, and calcification of atherosclerotic plaques.

14 . The method of claim 1 , wherein increase in serum PPi levels reduces pathological calcification of soft tissue in the subject.

15 . The method of claim 14 , wherein the soft tissue comprises one or more of atherosclerotic plaques, muscular arteries, joints of the hands, joints of the feet, spine, articular cartilage, connective tissue, and vertebral disk cartilage.

16 . The method of claim 1 , wherein the subject has a loss of function mutation in the gene encoding ecto-nucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1).

Assignments (1)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
Continuity (7)
Continuation 16813315 · Mar 9, 2020
Continuation 16033948 · Jul 12, 2018
Continuation 15686972 · Aug 25, 2017
Continuation 14765514
Provisional Application 61904786 · Nov 15, 2013
Provisional Application 61764297 · Feb 13, 2013
Related Publication 20220152163A1 · May 19, 2022
References Cited (81)
US 5428130A · Capon et al. · 1995 [cited by applicant]
US 5968508A · Goldfine et al. · 1999 [cited by applicant]
US 6043056A · Yue et al. · 2000 [cited by applicant]
US 6358923B1 · Yue et al. · 2002 [cited by applicant]
US 7323542B2 · Balian et al. · 2008 [cited by applicant]
US 7888372B2 · Millan et al. · 2011 [cited by applicant]
US 8846603B2 · Quinn et al. · 2014 [cited by applicant]
US 9744219B2 · Braddock et al. · 2017 [cited by applicant]
US 9913881B2 · Braddock et al. · 2018 [cited by applicant]
US 10064917B2 · Braddock et al. · 2018 [cited by applicant]
US 10213483B2 · Otterlei et al. · 2019 [cited by applicant]
US 10213484B2 · Braddock et al. · 2019 [cited by applicant]
US 10517927B2 · Braddock et al. · 2019 [cited by applicant]
US 10583170B2 · Braddock et al. · 2020 [cited by applicant]
US 10624958B2 · Braddock et al. · 2020 [cited by applicant]
US 20070015145A1 · Woolf et al. · 2007 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20140154774A1 · Quinn et al. · 2014 [cited by applicant]
US 20140377859A1 · Quinn et al. · 2014 [cited by applicant]
US 20150024460A1 · Quinn et al. · 2015 [cited by applicant]
US 20200138905A1 · Braddock et al. · 2020 [cited by applicant]
US 20220133854A1 · Braddock et al. · 2022 [cited by applicant]
EP 3298140A1 · 2018 [cited by applicant]
JP 2008188015A · 2008 [cited by applicant]
RU 2013142583A · 2015 [cited by applicant]
WO 0239994A2 · 2002 [cited by applicant]
WO 02092020A2 · 2002 [cited by applicant]
WO 03040340A2 · 2003 [cited by applicant]
WO 2006135925A2 · 2006 [cited by applicant]
WO 2008105911A2 · 2008 [cited by applicant]
WO 2011113027A2 · 2011 [cited by applicant]
WO 2012125182A1 · 2012 [cited by applicant]
WO 2014126965A2 · 2014 [cited by applicant]
WO 2016100803A2 · 2016 [cited by applicant]
WO 2016187408A1 · 2016 [cited by applicant]
Yang, et al. “Linker length affects expression and bioactivity of the onconase fusion protein in Pichia pastoris.” Genet Mol Res 14.4 (2015): 19360-19370. [cited by applicant]
European Supplemental Partial Search Report for European Patent Application No. 14751154.7 issued Nov. 7, 2016. [cited by applicant]
Extended European Search Report for European Patent Application No. 14751154.7 issued Feb. 16, 2017. [cited by applicant]
Extended European Search Report for European Patent Application No. 16797290.0 issued Jun. 25, 2019. [cited by applicant]
Mus musculus domesticus ecto-nucleotide pyrophosphatase/phosphodiesterase-1 mRNA, complete cds, GenBank J02700.2, 2020.08.12 searched. [cited by applicant]
Notice of Panel Decision from Pre-Appeal Brief Review for U.S. Appl. No. 15/812,456 issued Dec. 2, 2020. [cited by applicant]
Notice of Reasons for Rejection for Japanese Patent Application No. 2017-560327 dated Mar. 30, 2020, 5 pages. [cited by applicant]
PCT International Search Report and Written Opinion for PCT International Application No. PCT/US2014/015945 Issued Jul. 30, 2014. [cited by applicant]
PCT International Search Report and Written Opinion for PCT International Application No. PCT/US2016/033236 Issued Oct. 27, 2016. [cited by applicant]
Pre-Appeal Brief for U.S. Appl. No. 15/812,456, filed Oct. 16, 2020. [cited by applicant]
“Chronic Renal Failure: From the Perspective of Internal Medicine”, Clinical Imagiology 21(11), 2005, 1142-1149 (Partial Translation). [cited by applicant]
“Pharmacokinetic Control of Biopharmaceuticals”, Journal of Pharmaceutical Science and Technology, Japan, 2014, 27-32 (Partial Translation). [cited by applicant]
Albright, et al., “ENPP1-Fc prevents mortality and vascular calcifications in rodent model of generalized arterial calcification of infancy”, Nat Commun. 6, 2015, 10006. [cited by applicant]
Albright, et al., “Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke”, J Biol Chem. 289(6), 2014, 3294-3306. [cited by applicant]
Albright, et al., “NPP4 is a procoagulant enzyme on the surface of vascular endothelium”, Blood. 120(22), 2012, 4432-4440. [cited by applicant]
Buckley, et al., “Plasma cell membrane glycoprotein PC-1. cDNA cloning of the human molecule, amino acid sequence, and chromosomal location”, J Biol Chem. 265(29), Oct. 1990, 17506-17511. [cited by applicant]
Calvert, et al., “The Provisional Patent Application: What You Need to Know”, Inventors Eye. United States Patent and Trademark Office <www.uspto.gov/ learning-and-resources/newsletter/inventors-eye/provisional-patent-a… [cited by applicant]
Cimpean, et al., “Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2”, Biochem J. 381(Pt 1), 2004, 71-77. [cited by applicant]
Gijsbers, et al., “Functional characterization of the non-catalytic ectodomains of the nucleotide pyrophosphatase/phosphodiesterase NPP1”, Biochem J. 371(Pt 2), Apr. 15, 2003, 321-330. [cited by applicant]
Goding, et al., “Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family”, Biochim Biophys Acta. 1638(1), 2003, 1-19. [cited by applicant]
Jansen, et al., “Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing ysophospholipase D”, J Cell Sci. 118(Pt 14), 2005, 3081-3089. [cited by applicant]
Jansen, et al., “Structure of NPP1, an ectonucleotide pyrophosphatase/phosphodiesterase involved in tissue calcification”, Structure. 20(11), 2012, 1948-1959. [cited by applicant]
Johnson, et al., “Differential mechanisms of inorganic pyrophosphate production by plasma cell membrane glycoprotein-1 and B10 in chondrocytes”, Arthritis Rheum. 42(9), 1999, 1986-1997. [cited by applicant]
Johnson, et al., “Kabat database and its applications: 30 years after the first variability plot”, Nucleic Acids Res. 28(1), Jan. 2000, 214-218. [cited by applicant]
Johnson, et al., “Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression”, J Bone Miner Res. 18(6), 2003, 994-1004. [cited by applicant]
Johnson, et al., “Matrix vesicle plasma cell membrane glycoprotein-1 regulates mineralization by murine osteoblastic MC3T3 cells”, J Bone Miner Res. 14(6), Jun. 1999, 883-892. [cited by applicant]
Kato, et al., “Crystal structure of Enpp1, an extracellular glycoprotein involved in bone mineralization and insulin signaling”, Proc Natl Acad Sci U S A. 109(42), Oct. 2012, 16876-16881. [cited by applicant]
Lee, et al., “Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells”, Biochem Biophys Res Commun. 218(3, 1996, 714-719. [cited by applicant]
Li, et al., “Inhibition of Tissue-Nonspecific Alkaline Phosphatase Attenuates Ectopic Mineralization in the Abcc6 −/− Mouse Model of PXE but Not in the Enpp1 Mutant Mouse Models of Gaci”, J Invest Dermatol. 139(2), Feb.… [cited by applicant]
Millán, et al., “Enzyme replacement therapy for murine hypophosphatasia”, J Bone Miner Res. 23(6), Jun. 2008, 777-787. [cited by applicant]
Okawa, et al., “Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine”, Nat Genet. 19(3), Jul. 1998, 271-273. [cited by applicant]
Schetter, et al., “Nucleoporins NPP-1, NPP-3, NPP-4, NPP-11 and NPP-13 are required for proper spindle orientation in C. elegans”, Dev Biol. 289(2), Jan. 15, 2006, 360-371. [cited by applicant]
Shankar, et al., “Progeria—A Brief Review”, International Journal of Pharma and Bio Sciences 2, 2010, 1-14. [cited by applicant]
Stefan, et al., “NPP-type ectophosphodiesterases: unity in diversity.”, Trends Biochem Sci. 30(10), Oct. 2005, 542-550. [cited by applicant]
Terkeltaub, “Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification.”, Purinergic Signal. 2(2), Jun. 2, 2006, 371-377. [cited by applicant]
Van Meeteren, et al., “Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate”, J Biol Chem. 280(22), Jun. 2005, 21155-21161. [cited by applicant]
Whisstock, et al., “Prediction of proteinfunction fromprotein sequence and structure”, Quarterly Reviews of Biophysics 36, 3 (2003), pp. 2003, 307-340. [cited by applicant]
Witkowski, et al., “Conversion of a Beta-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine With Glutamine”, Biochemistry 38(36), Sep. 1999, 11643-11650. [cited by applicant]
Zhang, et al., “The interaction of cationic polymers and their bisphosphonate derivatives with hydroxyapatite”, Macromol Biosci. 7(5), May 10, 2007, 656-670 (Abstract Only). [cited by applicant]
Rogers, Brian, et al. “Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy.” Current pharmaceutical design 21.14 (2015): 1899-1907. Abstract. [cited by applicant]
Canadian Office Action issued on Jun. 1, 2022, for Canadian Patent Application No. 2,984,947. [cited by applicant]
Johnson, et al. “The nucleoside triphosphate pyrophosphohydrolase isozyme PC-1 directly promotes cartilage calcification through chondrocyte apoptosis and increased calcium precipitation by mineralizing vesicles.” The J… [cited by applicant]
Mackenzie, et al. “New insights into NPP1 function: lessons from clinical and animal studies.” Bone 51.5 (2012): 961-968. [cited by applicant]
Nitschke, Y et al. “Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6.” The American Journal of Human Genetics 90.1 (2012): 25-39. [cited by applicant]
Nitschke, et al. “Generalized arterial calcification of infancy and pseudoxanthoma elasticum: two sides of the same coin.” Frontiers in genetics 3 (2012): 302. [cited by applicant]
Rutsch, et al. “Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel.” Circulation research 109.5 (2011): 578-592. [cited by applicant]